| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
PI3K-IN-46 specifically targets PI3Kγ, an isoform of PI3K that is primarily expressed in leukocytes and is involved in cell migration, inflammation, and immune responses. By inhibiting PI3Kγ, it can modulate signaling pathways that are critical for the function of immune cells. Its role as a synthetic intermediate means its direct biological activity is often studied in the context of the final inhibitors it helps produce.
|
|---|---|
| ln Vitro |
In vitro, PI3K-IN-46 is a specific inhibitor of PI3Kγ. Its activity is typically assessed using biochemical kinase assays that measure the phosphorylation of a substrate in the presence of the compound. However, as an intermediate, its primary use is in chemical synthesis rather than direct biological assays. Its potency and selectivity are often characterized in the context of the final drug candidates derived from it.
|
| ln Vivo |
In vivo activity of PI3K-IN-46 is not directly studied, as it is primarily a synthetic intermediate. Its in vivo effects would be inferred from the activity of the PI3K inhibitors that are synthesized from it. These final compounds are used in animal models of autoimmune, cardiovascular, and neurodegenerative diseases to study their therapeutic potential.
|
| Enzyme Assay |
Cell-free assays for PI3K-IN-46 are not typically performed, as it is an intermediate rather than a final drug candidate. However, to characterize its inhibitory activity, biochemical kinase assays could be used to measure its effect on PI3Kγ phosphorylation of a substrate. The compound's IC50 value would be determined by measuring the phosphorylation in the presence of varying concentrations of the inhibitor.
|
| Cell Assay |
In vitro cellular assays are not typically conducted with PI3K-IN-46, as it is a synthetic intermediate. Its effects on cellular function would be studied using the final PI3K inhibitors derived from it. These cellular assays would involve treating cells with the final compounds and measuring downstream signaling, cell proliferation, or migration, depending on the disease model.
|
| Animal Protocol |
In vivo animal experiments are not typically performed with PI3K-IN-46, as it is a synthetic intermediate. The final PI3K inhibitors synthesized from this intermediate are tested in animal models of autoimmune, cardiovascular, and neurodegenerative diseases to evaluate their efficacy and safety.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of PI3K-IN-46 are not characterized, as it is a synthetic intermediate. Its molecular weight is 255.3, and it is soluble in DMSO at 2.55 mg/mL (10 mM). Its properties are relevant for its use in chemical synthesis rather than for in vivo administration.
|
| Toxicity/Toxicokinetics |
The toxicity profile of PI3K-IN-46 is not documented, as it is a synthetic intermediate. Its safety is evaluated in the context of the final drug products derived from it. Standard laboratory safety precautions should be observed when handling this chemical.
|
| References | |
| Additional Infomation |
PI3K-IN-46 is a synthetic intermediate used in the preparation of PI3K inhibitors, specifically 2-iminazolinone vinyl fused benzene analogues. These analogues are investigated for their potential in treating autoimmune diseases, cardiovascular diseases, and neurodegenerative diseases. The compound is used for research purposes and is not intended for human consumption.
|
| Molecular Formula |
C13H9N3OS
|
|---|---|
| Molecular Weight |
255.30
|
| Exact Mass |
255.046
|
| CAS # |
304645-61-2
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
2.1
|
| SMILES |
C1=CC2=C(C=CC(=C2)/C=C\3/C(=O)N=C(S3)N)N=C1
|
| InChi Key |
GWSGFSPSQGXVFI-XFFZJAGNSA-N
|
| InChi Code |
InChI=1S/C13H9N3OS/c14-13-16-12(17)11(18-13)7-8-3-4-10-9(6-8)2-1-5-15-10/h1-7H,(H2,14,16,17)/b11-7-
|
| Chemical Name |
(5Z)-2-amino-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.9170 mL | 19.5848 mL | 39.1696 mL | |
| 5 mM | 0.7834 mL | 3.9170 mL | 7.8339 mL | |
| 10 mM | 0.3917 mL | 1.9585 mL | 3.9170 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
